TP53, in particular, has been frequently reported to harbor somatic mutations in leiomyosarcomas, and its presence has been proposed as a distinguishing factor between benign leiomyomas and malignant leiomyosarcomas. This evidence concerns the gene TP53 and leiomyoma.